Vivus Jumps as FDA Allows Wider Sales of Obesity Drug

Vivus Inc. rose the most since March 6 after U.S. regulators said the drugmaker can sell its obesity pill Qsymia in more pharmacies than first allowed.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.